MLYS•benzinga•
Mineralys Therapeutics Announced Topline Data From Its Pivotal Launch-HTN Phase 3 And Pivotal Advance-HTN Phase 2 Trials Of Lorundrostat For Uncontrolled Hypertension Or Resistant Hypertension, Both Trials Met Its Primary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga